Castle Biosciences (CSTL) News Today → America’s worst nightmare? (From Porter & Company) (Ad) Free CSTL Stock Alerts $24.25 +0.01 (+0.04%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 10, 2024 | finance.yahoo.comCastle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for "Best Overall Mental Health Solution"May 10, 2024 | businesswire.comCastle Biosciences' IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”May 10, 2024 | americanbankingnews.comDaniel Bradbury Sells 23,323 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) StockMay 9, 2024 | insidertrades.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 2,368 SharesMay 8, 2024 | marketbeat.comDerek J. Maetzold Sells 2,368 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) StockCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 2,368 shares of the business's stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $24.72, for a total value of $58,536.96. Following the transaction, the insider now owns 62,629 shares in the company, valued at approximately $1,548,188.88. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.May 8, 2024 | finance.yahoo.comLargest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class ResultMay 7, 2024 | finance.yahoo.comWall Street Analysts Predict a 36.09% Upside in Castle Biosciences (CSTL): Here's What You Should KnowMay 5, 2024 | finance.yahoo.comEarnings Beat: Castle Biosciences, Inc. (NASDAQ:CSTL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 5, 2024 | msn.comCastle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call TranscriptMay 5, 2024 | americanbankingnews.comCastle Biosciences (NASDAQ:CSTL) PT Raised to $34.00 at Robert W. BairdMay 3, 2024 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Price Target Raised to $34.00 at Robert W. BairdRobert W. Baird boosted their price target on shares of Castle Biosciences from $33.00 to $34.00 and gave the company an "outperform" rating in a research report on Friday.May 3, 2024 | businesswire.comDecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and NeckMay 2, 2024 | investorplace.comCSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | markets.businessinsider.comCastle Biosciences earnings: here's what Wall Street expectsMay 2, 2024 | finance.yahoo.comCastle Biosciences Inc (CSTL) Q1 2024 Earnings: Surpasses Revenue Forecasts and Raises Annual ...May 2, 2024 | businesswire.comCastle Biosciences Reports First Quarter 2024 ResultsApril 30, 2024 | finance.yahoo.comCastle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT MelanomaApril 30, 2024 | businesswire.comCastle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT MelanomaApril 29, 2024 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Trading 6.3% Higher Castle Biosciences (NASDAQ:CSTL) Trading 6.3% HigherApril 27, 2024 | investing.comCastle Biosciences CEO Derek Maetzold sells shares worth over $22,000April 27, 2024 | seekingalpha.comCSTL Castle Biosciences, Inc.April 21, 2024 | marketbeat.comKnights of Columbus Asset Advisors LLC Has $2.29 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Knights of Columbus Asset Advisors LLC boosted its position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 99.2% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 106,262 shares of the company's stock after purchasing an additionaApril 20, 2024 | marketbeat.comKornitzer Capital Management Inc. KS Trims Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Kornitzer Capital Management Inc. KS reduced its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 16.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 542,874 shares of the companyApril 18, 2024 | investing.comCastle Biosciences CEO sells over $100k in company stockApril 18, 2024 | insidertrades.comInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 1,947 Shares of StockApril 17, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $39,621.45 in StockCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 1,947 shares of the firm's stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $20.35, for a total value of $39,621.45. Following the sale, the insider now owns 65,418 shares of the company's stock, valued at approximately $1,331,256.30. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.April 17, 2024 | finance.yahoo.comWe're Not Worried About Castle Biosciences' (NASDAQ:CSTL) Cash BurnApril 11, 2024 | businesswire.comCastle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024April 11, 2024 | insidertrades.comCastle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury Sells 2,400 SharesApril 10, 2024 | finance.yahoo.comCastle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational CollaborationsApril 10, 2024 | businesswire.comCastle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational CollaborationsApril 10, 2024 | finance.yahoo.comCastle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive YearApril 10, 2024 | businesswire.comCastle Biosciences' Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive YearApril 10, 2024 | investing.comCastle Biosciences director sells over $440k in company stockApril 9, 2024 | insidertrades.comCastle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury Sells 9,152 SharesApril 6, 2024 | marketbeat.comTritonpoint Wealth LLC Buys Shares of 94,356 Castle Biosciences, Inc. (NASDAQ:CSTL)Tritonpoint Wealth LLC purchased a new position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 94,356 shares of the company's stock, valued at apApril 6, 2024 | insidertrades.comInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 2,368 Shares of StockApril 5, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $51,385.60 in StockCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 2,368 shares of the company's stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $21.70, for a total value of $51,385.60. Following the completion of the transaction, the insider now owns 67,365 shares in the company, valued at approximately $1,461,820.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.April 5, 2024 | finance.yahoo.comWhat Makes Castle Bioscience (CSTL) a Prospective Investment?April 4, 2024 | finance.yahoo.comPresentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin CancerApril 4, 2024 | businesswire.comPresentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin CancerMarch 31, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Sees Significant Increase in Short InterestCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 1,420,000 shares, an increase of 17.4% from the February 29th total of 1,210,000 shares. Based on an average daily volume of 252,100 shares, the short-interest ratio is presently 5.6 days.March 27, 2024 | businesswire.comCastle Biosciences Announces Updates to its Board of DirectorsMarch 26, 2024 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Shares Up 5.4%Castle Biosciences (NASDAQ:CSTL) Trading Up 5.4%March 25, 2024 | finance.yahoo.comCastle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive YearMarch 24, 2024 | insidertrades.comDerek J. Maetzold Sells 2,295 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) StockMarch 22, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 2,295 SharesCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 2,295 shares of Castle Biosciences stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $20.27, for a total transaction of $46,519.65. Following the sale, the insider now directly owns 69,806 shares in the company, valued at approximately $1,414,967.62. The sale was disclosed in a legal filing with the SEC, which is available at this link.March 22, 2024 | businesswire.comLong-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNBMarch 20, 2024 | finance.yahoo.comDoes Castle Bioscience (CSTL) Have Robust Growth Prospects?March 19, 2024 | businesswire.comLeading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now CSTL Media Mentions By Week CSTL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CSTL News Sentiment▼0.720.57▲Average Medical News Sentiment CSTL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CSTL Articles This Week▼114▲CSTL Articles Average Week Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Fulgent Genetics News CareDx News Celcuity News Viridian Therapeutics News Sera Prognostics News Biodesix News Genetron News Personalis News Renalytix News Exagen News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CSTL) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersElon’s New Device is About to Shock the WorldInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressCharles Payne Demystifies OptionsUnstoppable ProsperityThe only AI company you should be looking atBehind the MarketsNo experience to confident trader, meet my student…Wealth Builders InstituteCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOIC Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
